Sign in
EK

EASTMAN KODAK CO (KODK)·Q3 2025 Earnings Summary

Executive Summary

  • Q3 2025 revenue was $269.0M (+3% YoY), gross profit rose to $68.0M (+51% YoY) with gross margin expanding 800 bps to 25%; Operational EBITDA surged to $29.0M from $1.0M YoY, while GAAP net income declined to $13.0M (from $18.0M) due to lower non‑cash pension income and higher interest expense .
  • Balance sheet de‑risking advanced materially: Kodak expects ~$600M pension reversion proceeds (raised from $500M), plans to cut term loans to ~$200M and end 2025 with >$300M cash, resolving prior going‑concern disclosure .
  • AM&C led growth (revenues +15% YoY), and the cGMP pharma facility is now certified to manufacture and sell regulated products; Print margin improved on pricing, lower aluminum costs and lower SG&A despite modest revenue decline .
  • Street consensus for Q3 EPS and revenue was not available; comparisons to estimates are therefore not possible (values retrieved from S&P Global).*

What Went Well and What Went Wrong

What Went Well

  • Gross margin expanded to 25% from 17% YoY on pricing, volume gains and lower aluminum costs, driving gross profit to $68.0M (+$23.0M YoY) and Operational EBITDA to $29.0M (+$28.0M YoY) .
  • AM&C revenue grew 15% YoY to $82.0M, with Operational EBITDA up $10.0M; management highlighted certification of the cGMP pharmaceutical facility to manufacture and sell regulated products and a direct‑to‑distributor launch in still film to stabilize supply and pricing .
  • Balance sheet milestones: progress on pension settlement (annuities/lump sums executed), expected ~$600M reversion, plan to reduce term loans to ~$200M, and going‑concern conditions fully resolved; CFO expects >$300M year‑end cash and net positive cash versus term loans and Series B preferred obligations .

What Went Wrong

  • GAAP net income fell to $13.0M (from $18.0M YoY) and diluted EPS to $(0.08) (from $0.15 YoY), driven by a $26.0M YoY decrease in non‑cash pension income and higher interest expense (+$4.0M YoY) .
  • Print revenue decreased 3% YoY to $177.0M on lower Prepress Solutions volume (though segment Operational EBITDA improved $17.0M YoY via pricing, lower aluminum and SG&A) .
  • No formal Q&A on the earnings call, limiting real‑time visibility into demand outlook and order trends; management directed investors to the 10‑Q for details .

Financial Results

Quarterly Progression (oldest → newest)

MetricQ1 2025Q2 2025Q3 2025
Revenue ($USD Millions)$247 $263 $269
Gross Profit ($USD Millions)$46 $51 $68
Gross Margin %19% 19% 25%
GAAP Net Income ($USD Millions)$(7) $(26) $13
Diluted EPS ($USD)$(0.12) $(0.36) $(0.08)
Operational EBITDA ($USD Millions)$2 $9 $29
Cash and Equivalents ($USD Millions)$158 $155 $168

Year-over-Year Comparison (Q3 2025 vs Q3 2024)

MetricQ3 2024Q3 2025
Revenue ($USD Millions)$261 $269
Gross Profit ($USD Millions)$45 $68
Gross Margin %17% 25%
GAAP Net Income ($USD Millions)$18 $13
Diluted EPS ($USD)$0.15 $(0.08)
Operational EBITDA ($USD Millions)$1 $29

Segment Breakdown (Q3 2025 vs Q3 2024; excludes Eastman Business Park)

SegmentRevenue Q3 2024 ($M)Revenue Q3 2025 ($M)Operational EBITDA Q3 2024 ($M)Operational EBITDA Q3 2025 ($M)
Print$182 $177 $(9) $8
Advanced Materials & Chemicals$71 $82 $6 $16
Brand$5 $6 $4 $5
Total (segment table)$258 $265 $1 $29

Note: Segment table excludes Eastman Business Park; consolidated revenue was $269M vs the $265M total from reportable segments .

Additional KPIs (Q3 2025 vs Q3 2024)

KPIQ3 2024Q3 2025
SG&A ($USD Millions)$44 $41
R&D ($USD Millions)$8 $7
Interest Expense ($USD Millions)$14 $18
Pension Income excl. service ($USD Millions)$(42) $(16)

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Pension reversion proceedsDec 2025~$500M ~$600M; ~$450M cash + ~$150M non‑cash (hedge funds) Raised
Reversion timingDec 2025Anticipated completion by Dec 2025 On plan for Dec 2025 Maintained
Term loans principalPost‑reversionN/AReduce to ~$200M principal New
YE 2025 cash balanceYE 2025N/A>$300M New
Net cash vs term loans & Series BPost‑reversionN/ANet positive cash position vs term loans and Series B New
Going‑concern disclosureQ2 2025 vs Q3 2025Substantial doubt disclosed in Q2 Fully resolved in Q3 Improved

Earnings Call Themes & Trends

TopicPrevious Mentions (Q1 & Q2 2025)Current Period (Q3 2025)Trend
AM&C growth and cGMP pharmaQ1: Facility expected online later in 2025; AM&C leveraging layering/coating . Q2: FDA registration; certified to manufacture regulated products; starting with PBS .Facility now certified to manufacture and sell regulated products; starting with diagnostic reagents; AM&C revenue +15% YoY .Strengthening execution
Film business strategyLimited in Q1; Q2 focus on AM&C and tariffs .Launch of direct distribution for still films; doubled finishing capacity; motion picture and still film demand rising .Expansion and vertical control
Print businessQ1: “Smart revenue” focus; streamlining operations . Q2: Print revenue –3% YoY; Prepress volume pressure (segment table) .Print revenue –3% YoY; Operational EBITDA +$17M YoY via pricing, lower aluminum and SG&A .Margin recovery despite softer volume
Pension reversion & balance sheetQ1: KRIP termination progressing . Q2: Reversion anticipated by Dec 2025; going‑concern disclosed .Annuity/lump sum settlements executed; expected ~$600M reversion; going‑concern fully resolved .De‑risking and liquidity improvement
Tariffs/macroQ2: Tariffs not material in Q2; assessing future impact .No new tariff update in Q3 release; macro uncertainties acknowledged .Neutral/Cautious
Legal/litigation costsQ2: Insurance reimbursement reduced consulting costs .Lower spend on certain litigation matters cited as EBITDA tailwind .Tailwind

Management Commentary

  • CEO (Jim Continenza): “Kodak delivered strong performance... our AM&C business continued to grow... cGMP pharmaceutical manufacturing facility is now certified... launched still films... providing... more stable pricing and a broader, more reliable supply... The next step will be to use the surplus assets from the reversion to pay down debt and strengthen our balance sheet.” .
  • CFO (David Bullwinkle): “The cash from the pension reversion will reduce our term debt to $200 million, lowering interest expense and improving liquidity, resulting in our healthiest balance sheet in years... We remain committed to a disciplined approach to cash management, driving operational efficiencies and margin improvement...” .
  • CEO (call): “We now expect to get approximately $600 million... about $450 million in cash and $150 million in hedge funds... Once everything is settled, we expect to be net cash positive.” .
  • CFO (call): “We expect to end 2025 with a cash balance of more than $300 million... Kodak will then be in a net positive cash position with respect to the term loans and our Series B preferred stock obligations.” .

Q&A Highlights

  • No formal Q&A was held; management directed investors to the 10‑Q and IR team for follow‑up .
  • Clarifications provided in prepared remarks: detailed pension settlement steps completed (annuities and lump sums), expected ~$600M reversion and usage priorities, extension of loan maturities, and resolution of going‑concern disclosure .
  • Operating drivers: pricing and volume improvements, lower aluminum costs, reduced litigation spend, and prior‑period inventory reserve adjustment boosted Operational EBITDA; higher manufacturing costs were a partial offset .

Estimates Context

  • S&P Global consensus for Q3 2025 EPS and revenue was unavailable; the data feed returned no estimates and only actuals for revenue, so a beat/miss assessment versus Street is not possible (values retrieved from S&P Global).*
  • Given the step‑change in gross margin and Operational EBITDA, any future estimates are likely to incorporate improved pricing discipline and lower commodity costs; however, without current consensus coverage, we cannot quantify revisions. .

Key Takeaways for Investors

  • Material operating improvement: gross margin expanded to 25% and Operational EBITDA rose to $29.0M, reflecting pricing power, lower aluminum costs, and AM&C momentum—key drivers for near‑term narrative and potential multiple support .
  • Balance sheet inflection: expected ~$600M pension reversion, YE 2025 cash >$300M, and term loans trimmed to ~$200M collectively remove solvency overhang and reduce interest burden—catalysts for sentiment and credit risk repricing .
  • AM&C strategy is delivering: pharma facility certification and direct film distribution improve mix and control; AM&C revenue +15% YoY with EBITDA strength—watch capacity ramp and regulated product pipeline .
  • Print recovery via margin: despite a 3% YoY revenue decline, Print EBITDA improved $17M YoY on pricing, commodity relief, and SG&A discipline—monitor sustainability amid Prepress volume pressure .
  • GAAP optics: net income fell YoY and diluted EPS was negative to common shareholders despite positive net earnings, reflecting pension income normalization and higher interest expense—investors should focus on non‑GAAP operational trends and balance sheet de‑risking .
  • No Q&A reduces visibility; rely on 10‑Q disclosures for detail on pension reversion mechanics, debt maturities and covenant compliance; management states continued compliance .
  • Near‑term trading lens: stock narrative likely pivots toward margin durability and de‑risked balance sheet; medium‑term thesis hinges on AM&C growth (pharma/film) and sustained pricing power in Print .
*Values retrieved from S&P Global.